CQN-SHIPPEO
18.6.2024 18:12:30 CEST | Business Wire | Press release
Last subhead bullet point of release dated June 18, 2024 should read: Adding subcontractor visibility independent of telematics solution (instead of "Subcontractors gain visibility independent of the telematics solution they use").
The updated release reads:
ZF’S SCALAR GAINS ENHANCED CARGO VISIBILITY WITH SHIPPEO
- ZF SCALAR’s orchestration platform enhances cargo tracking by leveraging Shippeo
- Carriers benefit from highly accurate real-time operational visibility over their flows, and predictive Estimated Time of Arrival (ETA) information
- Adding subcontractor visibility independent of telematics solution
ZF's SCALAR orchestration platform offers advanced cargo track-and-trace capabilities, powered by leveraging Shippeo’s multimodal real-time transportation visibility solution. This enhanced platform provides carriers with highly accurate, real-time visibility of their consignments, enabling them to build more resilient and customer-centric supply chains.
The collaboration effectively integrates Shippeo’s advanced tracking technologies spanning road, air, and ocean shipments into ZF's SCALAR orchestration platform. By providing real-time and predictive visibility, logistics providers can minimize potential delays while optimizing line-haul and delivery efficiencies and improve on-time deliveries.
Hjalmar van Raemdonck, ZF’s VP SCALAR in the division Commercial Vehicle Solutions said: “The integration of Shippeo’s real-time visibility into the SCALAR orchestration platform helps to simplify the complexities of modern logistics, enabling carriers to strengthen the resilience and reliability of their line-haul networks. By providing an additional layer of visibility, our logistics customers will be able to orchestrate their fleets with enhanced precision, enabling them to optimize routes, minimize delays, and improve overall supply chain efficiency.”
Pierre Khoury, CEO & Co-founder Shippeo: "We're incredibly proud to collaborate with a global automotive leader like ZF. By leveraging Shippeo's advanced visibility platform, ZF will be empowered to optimize carrier transportation capacity, ensuring on-time delivery at the best possible price. Furthermore, Shippeo's end-to-end visibility will provide ZF with a more sustainable supply chain.”
Integrating cargo visibility into SCALAR provides carriers equal real-time ETA visibility for both trailer and truck. Carriers relying solely on trailer tracking solutions find it particularly advantageous, especially when trailers are picked up by different trucks, whether equipped with telematics or not. With the Shippeo integration carriers also gain valuable insights into subcontractor performance, enabling them to streamline their operational processes. Furthermore carriers have easy access to accurate CO2 emission reports per transport order, enabling them to reduce their environmental impact.
About ZF
ZF is a global technology company supplying systems for passenger cars, commercial vehicles and industrial technology, enabling the next generation of mobility. ZF allows vehicles to see, think and act. In the four technology domains of Vehicle Motion Control, Integrated Safety, Automated Driving, and Electric Mobility, ZF offers comprehensive product and software solutions for established vehicle manufacturers and newly emerging transport and mobility service providers. ZF electrifies a wide range of vehicle types. With its products, the company contributes to reducing emissions, protecting the climate and enhancing safe mobility. With some 165,000 employees worldwide, ZF reported sales of €43.8 billion in fiscal 2022. The company operates 168 production locations in 32 countries. For further press information and photos, please visit: www.zf.com
About CVS Division
ZF’s Commercial Vehicle Solutions (CVS) division is helping shape the future of commercial transportation ecosystems. Our mission is to be the preferred global technology partner to the commercial vehicle industry. Powerfully combining ZF’s commercial vehicle systems expertise, extensive technology portfolio and global operations, the division serves the full commercial vehicle industry value chain. As the automotive industry progresses towards an increasingly autonomous, connected, and electrified (ACE) future, ZF’s CVS division innovates, integrates and supplies components and advanced control systems that help make commercial vehicles and fleets operate more safely and sustainably. CVS unites ZF’s former Commercial Vehicle Technology and Commercial Vehicle Control Systems divisions, the latter being formed following ZF’s acquisition of WABCO in Spring 2020.
About Shippeo
Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more resilient, sustainable, and customer-centric supply chains. This is made possible with highly accurate real-time operational visibility and Transport Process Automation™ to streamline transportation processes, reduce latency and improve operational efficiency. Their Multimodal Visibility Network integrates with more than 1,000 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Ahold Delhaize, AkzoNobel, Amazon, Avery Dennison, Arlanxeo, Barilla, Birra Peroni, Bosch Siemens Hausgeräte, Carrefour, Coca-Cola HBC, DP World, Evonik, Fujifilm, Jaguar Land Rover, Hartmann Group, Heineken, Kuehne+Nagel, L’Oréal, LVMH, Renault Group, Sabic, Saint-Gobain, XPO Logistics and Yamaha Motor, trust Shippeo to track more than 50 million shipments per year across 130 countries. Learn more at www.shippeo.com,
LinkedIn, Facebook, X (formerly Twitter)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618974800/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
